Brimonidine/Timolol: a viewpoint by Francisco J. Goñi.
Goñi
Francisco J
FJ
Barcelona Glaucoma Center-Institut Oftalmòlògic de Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain.
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use; D000068438:Brimonidine Tartrate; D004359:Drug Therapy, Combination; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D009798:Ocular Hypertension / Q000188:drug therapy*; D011810:Quinoxalines / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use; D013999:Timolol / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D011810:Quinoxalines; D013449:Sulfonamides; D013876:Thiophenes; D000068438:Brimonidine Tartrate; D013999:Timolol; C062765:dorzolamide